{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:53Z","timestamp":1792784633834,"version":"4.5.0"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Chengdu Medical College Talent Climbing Program","award":["2024qnGzn11"],"award-info":[{"award-number":["2024qnGzn11"]}],"id":[{"id":"https:\/\/ror.org\/01c4jmp52","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["82204308"],"award-info":[{"award-number":["82204308"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sichuan Science and Technology Program","award":["2024NSFSC2105"],"award-info":[{"award-number":["2024NSFSC2105"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The effectiveness of liposome-based antitumor drugs is significantly limited by the poor tumor accumulation of liposomes. Herein, we report that resiquimod (R848) can selectively increase tumor accumulation of 7-Ethyl-10-hydroxycamptothecin (SN38)-loaded liposomes (SN38-LIPs) without significantly altering their pharmacokinetics. R848 enhanced the tumor distribution of SN38-LIPs and free SN38 by approximately 5-fold and 10-fold, respectively. This further resulted in greatly improved in vivo antitumor activity compared with those treated with R848 or SN38-LIPs alone (tumor inhibition rate: \u223c95% versus \u223c50%). The increased antitumor activity was associated with increased serum TNF-\u03b1 and enhanced macrophage infiltration in the tumor. These results suggested that R848 held great potential to enhance the clinical antitumor effect of nanomedicine by increasing its tumor accumulation.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00679","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:03:10Z","timestamp":1790179390000},"page":"5058-5068","source":"Crossref","is-referenced-by-count":0,"title":["Resiquimod Improves the Tumor Accumulation and Antitumor Activity of SN38 Prodrug-Loaded Liposomes"],"prefix":"10.1021","volume":"23","author":[{"given":"Tao","family":"Yang","sequence":"first","affiliation":[{"name":"Chongqing Medical University , , ,","place":["Chongqing, China, 400016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Xu","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Chengdu Medical College, Chengdu, 610500, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlin","family":"Wang","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Huang","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Abamo","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Man","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-848X","authenticated-orcid":true,"given":"Yaxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Chengdu Medical College , , ,","place":["Chengdu, China, 610500"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-1297","authenticated-orcid":true,"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Chongqing Medical University , , ,","place":["Chongqing, China, 400016"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100509324714400_cit1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jconrel.2024.10.037","article-title":"Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment","volume":"376","author":"Jourdain","year":"2024","journal-title":"J. Controlled Release"},{"key":"2026100509324714400_cit2","doi-asserted-by":"publisher","first-page":"122801","DOI":"10.1016\/j.biomaterials.2024.122801","article-title":"Liposomes-enabled cancer chemoimmunotherapy","volume":"313","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"2026100509324714400_cit3","doi-asserted-by":"publisher","first-page":"125248","DOI":"10.1016\/j.ijpharm.2025.125248","article-title":"Effects of linkers on the development of liposomal docetaxel-glutathione prepared by active click loading","volume":"671","author":"Zhou","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"5","key":"2026100509324714400_cit4","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1021\/acs.molpharmaceut.3c01140","article-title":"The Effect of Lipid Composition on the Liposomal Delivery of Camptothecin Developed by Active Click Loading","volume":"21","author":"Xie","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"3","key":"2026100509324714400_cit5","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for Tumor Targeted Therapy: A Review","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"2026100509324714400_cit6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2019.12.023","article-title":"The role of liposomes in clinical nanomedicine development. What now? Now what?","volume":"318","author":"Crommelin","year":"2020","journal-title":"J. Controlled Release"},{"issue":"12 Pt 1","key":"2026100509324714400_cit7","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism oftumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"2026100509324714400_cit8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","author":"Fang","year":"2020","journal-title":"Adv. Drug Delivery Rev."},{"issue":"2","key":"2026100509324714400_cit9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17425247.2021.1874916","article-title":"Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors","volume":"19","author":"Islam","year":"2022","journal-title":"Expert Opin. Drug Delivery"},{"key":"2026100509324714400_cit10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: A mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J. Controlled Release"},{"issue":"26","key":"2026100509324714400_cit11","doi-asserted-by":"publisher","first-page":"8073","DOI":"10.7150\/thno.37198","article-title":"Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics"},{"issue":"26","key":"2026100509324714400_cit12","doi-asserted-by":"publisher","first-page":"8018","DOI":"10.7150\/thno.38587","article-title":"Transcytosis - An effective targeting strategy that is complementary to \u201cEPR effect\u201d for pancreatic cancer nano drug delivery","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"issue":"26","key":"2026100509324714400_cit13","doi-asserted-by":"publisher","first-page":"8091","DOI":"10.7150\/thno.37204","article-title":"Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery","volume":"9","author":"Dhaliwal","year":"2019","journal-title":"Theranostics"},{"key":"2026100509324714400_cit14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.addr.2017.07.007","article-title":"Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors","volume":"119","author":"Ojha","year":"2017","journal-title":"Adv. Drug Delivery Rev."},{"issue":"4","key":"2026100509324714400_cit15","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood.v100.4.1334.h81602001334_1334_1339","article-title":"Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF","volume":"100","author":"Friedl","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2026100509324714400_cit16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":"Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nat. Nanotechnol."},{"key":"2026100509324714400_cit17","doi-asserted-by":"publisher","first-page":"215051","DOI":"10.1016\/j.ccr.2023.215051","article-title":"Current understanding of passive and active targeting nanomedicines to enhance tumor accumulation","volume":"481","author":"Chen","year":"2023","journal-title":"Coord. Chem. Rev."},{"key":"2026100509324714400_cit18","doi-asserted-by":"publisher","first-page":"114449","DOI":"10.1016\/j.addr.2022.114449","article-title":"Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms","volume":"188","author":"Zi","year":"2022","journal-title":"Adv. Drug Delivery Rev."},{"issue":"4","key":"2026100509324714400_cit19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.drudis.2021.11.015","article-title":"Stromal disruption facilitating invasion of a \u2019nano-arsenal\u2019 into the solid tumor","volume":"27","author":"Fu","year":"2022","journal-title":"Drug Discovery Today"},{"key":"2026100509324714400_cit20","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jconrel.2025.02.064","article-title":"Tumor-stromal opening via S. typhimurium VNP20009 administration for complete inhibition of refractory tumor growth with liposomal anticancer drugs","volume":"380","author":"Kato","year":"2025","journal-title":"J. Controlled Release"},{"key":"2026100509324714400_cit21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2022.12.050","article-title":"Pre-treatment of oncolytic reovirus improves tumor accumulation and intratumoral distribution of PEG-liposomes","volume":"354","author":"Eguchi","year":"2023","journal-title":"J. Controlled Release"},{"issue":"7","key":"2026100509324714400_cit22","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1039\/d2mh00380e","article-title":"Remote drug loading into liposomes via click reaction","volume":"9","author":"Zheng","year":"2022","journal-title":"Mater. Horiz."},{"issue":"6","key":"2026100509324714400_cit23","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1021\/acs.molpharmaceut.5c00024","article-title":"Effect of Prodrug Activation Rate on In Vivo Drug Release and Antitumor Efficacy of SN38-Prodrug-Entrapped Liposomes","volume":"22","author":"Zhou","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026100509324714400_cit24","doi-asserted-by":"publisher","first-page":"113762","DOI":"10.1016\/j.jconrel.2025.113762","article-title":"Slow intravenous infusion reduces the accelerated blood clearance of PEGylated liposomes by removing anti-PEG antibodies","volume":"382","author":"Zheng","year":"2025","journal-title":"J. Controlled Release"},{"issue":"34","key":"2026100509324714400_cit25","doi-asserted-by":"publisher","first-page":"2500526","DOI":"10.1002\/smll.202500526","article-title":"Revealing the Incidence of the Accelerated Blood Clearance Phenomenon of PEGylated Liposomes in Individuals Using a Drug-Release Reporter Liposome","volume":"21","author":"Zheng","year":"2025","journal-title":"Small"},{"key":"2026100509324714400_cit26","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"2026100509324714400_cit27","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"2026100509324714400_cit28","doi-asserted-by":"publisher","first-page":"120856","DOI":"10.1016\/j.ijpharm.2021.120856","article-title":"Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation","volume":"606","author":"He","year":"2021","journal-title":"Int. J. Pharm."},{"key":"2026100509324714400_cit29","doi-asserted-by":"publisher","first-page":"111967","DOI":"10.1016\/j.colsurfb.2021.111967","article-title":"Redox-sensitive irinotecan liposomes with active ultra-high loading and enhanced intracellular drug release","volume":"206","author":"Wang","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"12","key":"2026100509324714400_cit30","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1016\/j.bmc.2017.04.025","article-title":"Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects","volume":"25","author":"Du","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"2026100509324714400_cit31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","article-title":"Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues","volume":"104","author":"Murdoch","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2026100509324714400_cit32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","article-title":"Inflammatory cytokines in vascular dysfunction and vascular disease","volume":"78","author":"Sprague","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"2026100509324714400_cit33","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.2910460624","article-title":"Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-\u03b1 in mice","volume":"46","author":"Suzuki","year":"1990","journal-title":"Int. J. Cancer"},{"issue":"6","key":"2026100509324714400_cit34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/1097-0215(20000915)87:6&lt;829::aid-ijc12&gt;3.0.co;2-c","article-title":"Low-dose tumor necrosis factor-\u03b1 augments antitumor activity of stealth liposomal doxorubicin (DOXIL\u00ae) in soft tissue sarcoma-bearing rats","volume":"87","author":"Ten Hagen","year":"2000","journal-title":"Int. J. Cancer"},{"key":"2026100509324714400_cit35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2024.07.015","article-title":"Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment","volume":"373","author":"Gu","year":"2024","journal-title":"J. Controlled Release"},{"issue":"5","key":"2026100509324714400_cit36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J. Leukocyte Biol."},{"key":"2026100509324714400_cit37","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.71424","article-title":"Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis","volume":"15","author":"Chan","year":"2026","journal-title":"Adv. Healthcare Mater."},{"key":"2026100509324714400_cit38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.actbio.2022.01.005","article-title":"Exosome-mediated delivery of transforming growth factor-\u03b2 receptor 1 kinase inhibitors and toll-like receptor 7\/8 agonists for combination therapy of tumors","volume":"141","author":"Lee","year":"2022","journal-title":"Acta Biomater."},{"key":"2026100509324714400_cit39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jconrel.2022.11.028","article-title":"Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy","volume":"353","author":"Si","year":"2023","journal-title":"J. Controlled Release"},{"key":"2026100509324714400_cit40","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jconrel.2020.11.013","article-title":"Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy","volume":"330","author":"Zhang","year":"2021","journal-title":"J. Controlled Release"},{"issue":"1","key":"2026100509324714400_cit41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ijc.1578","article-title":"Pegylated liposomal tumor necrosis factor-\u03b1 results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil\u00ae) in soft tissue sarcoma-bearing rats","volume":"97","author":"ten Hagen","year":"2002","journal-title":"Int. J. Cancer"},{"key":"2026100509324714400_cit42","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jconrel.2023.07.030","article-title":"Targeted co-delivery of resiquimod and a SIRP\u03b1 variant by liposomes to activate macrophage immune responses for tumor immunotherapy","volume":"360","author":"Jia","year":"2023","journal-title":"J. Controlled Release"},{"key":"2026100509324714400_cit43","doi-asserted-by":"publisher","first-page":"122708","DOI":"10.1016\/j.biomaterials.2024.122708","article-title":"Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy","volume":"311","author":"Li","year":"2024","journal-title":"Biomaterials"},{"issue":"1","key":"2026100509324714400_cit44","doi-asserted-by":"publisher","first-page":"a016345","DOI":"10.1101\/cshperspect.a016345","article-title":"Inflammation and the Blood Microvascular System","volume":"7","author":"Pober","year":"2015","journal-title":"old Spring Harbor Perspect. Biol."},{"issue":"10","key":"2026100509324714400_cit45","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/j.apsb.2021.04.023","article-title":"Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design","volume":"11","author":"Qiao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"2026100509324714400_cit46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41565-023-01498-w","article-title":"Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours","volume":"19","author":"Wang","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"2026100509324714400_cit47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11427-021-1976-0","article-title":"Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting","volume":"65","author":"Jiang","year":"2022","journal-title":"Sci. China Life Sci."},{"issue":"2","key":"2026100509324714400_cit48","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"2026100509324714400_cit49","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/j.xphs.2017.06.019","article-title":"Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection","volume":"106","author":"Natfji","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"2026100509324714400_cit50","doi-asserted-by":"publisher","first-page":"2409898","DOI":"10.1002\/advs.202409898","article-title":"Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine","volume":"12","author":"Cassani","year":"2025","journal-title":"Adv. Sci."},{"key":"2026100509324714400_cit51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jconrel.2017.08.003","article-title":"Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling","volume":"267","author":"Nichols","year":"2017","journal-title":"J. Controlled Release"},{"key":"2026100509324714400_cit52","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.drup.2020.100704","article-title":"Nanomedicine to target multidrug resistant tumors","volume":"52","author":"Lepeltier","year":"2020","journal-title":"Drug Resistance Updates"},{"issue":"1","key":"2026100509324714400_cit53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12951-021-01221-8","article-title":"Charge reversal nano-systems for tumor therapy","volume":"20","author":"Zhang","year":"2022","journal-title":"J. Nanobiotechnol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00679","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5058\/68625068\/mp6c00679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/5058\/68625068\/mp6c00679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:27Z","timestamp":1791208167000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/5058\/5436861\/Resiquimod-Improves-the-Tumor-Accumulation-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00679","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}